Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Liviane D de Azevedo, Debora I Leite, Andressa P de Oliveira, Floriano P S Junior, Rafael F Dantas, Monica M Bastos, Nubia Boechat, Luiz C F Pimentel
Imatinib mesylate was the first representative BCR-ABL1 tyrosine kinase inhibitor (TKI) class for the treatment of chronic myeloid leukemia. Despite the revolution promoted by TKIs in the treatment of this pathology, a resistance mechanism occurs against all BCR-ABL1 inhibitors, necessitating a constant search for new therapeutic options. To develop new antimyeloproliferative substances, we applied a medicinal chemistry tool known as molecular hybridization to design 25 new substances. These compounds were synthesized and biologically evaluated against K562 cells, which express BCR-ABL1, a constitutively active tyrosine kinase enzyme, as well as in WSS-1 cells (healthy cells)...
April 16, 2024: Archiv der Pharmazie
#2
JOURNAL ARTICLE
Syed Shariq Naeem, Pooja Gupta, Ranjit Kumar Sahoo, V L Kumar, T Velpandian, Archana Singh, Atul Batra, Raja Pramanik, Sameer Rastogi, Saumya Srivastava
INTRODUCTION: Hand foot skin reaction (HFSR) is a common dose-limiting adverse effect of multi kinase inhibitors (MKI) whose mechanism is not fully understood, and the prophylaxis is inadequate. OBJECTIVE: In this pilot study, a double-blind, randomized placebo-controlled trial was conducted to evaluate the effect of topical urea in secondary prevention of sunitinib-induced HFSR in renal cell cancer patients. METHODS: Out of 55 screened patients, 14 were randomized to receive topical urea or placebo for four weeks...
March 13, 2024: Clinical Genitourinary Cancer
#3
REVIEW
Xueqing Sun, Youqi Zhu, Yufei Lou, Xinyu Lu, Bo Wang, Dehong Yu, Yilong Guo, Yong Xin
PURPOSE: To evaluate literature evidences about the efficacy and safety of anti-angiogenesis agents plus chemoradiotherapy versus chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma. METHODS: The relevant literature was systematically searched from the date of establishment to April 2023 in PubMed, Embase, Web of Science, The Cochrane Library, Chinese National Knowledge Infrastructure, Chinese Biological Medicine, Wanfang and VIP database...
April 16, 2024: European Archives of Oto-rhino-laryngology
#4
JOURNAL ARTICLE
Qingfeng Fu, Gang Li, Lin Wang, Chunyang Yin, Bocun Yi, Yue Huang, Qiang Su, Zhihong Zhang, Jianqiang Zhu
Renal cell carcinoma (RCC) is one of the most common malignancies in the urinary system and is not sensitive to chemotherapy or radiotherapy in its advanced stages. Sunitinib is recommended as a first-line target drug for unresectable and metastatic RCC by targeting tyrosine kinase-related signaling pathways, but its therapeutic effect is unsatisfactory. Recently, nanomaterials have shown great prospects in the medical field because of their unique physicochemical properties. Particularly, liposomes are considered as ideal drug delivery systems due to their biodegradability, biocompatibility, and ideal drug-loading efficiency...
April 16, 2024: ACS Applied Materials & Interfaces
#5
JOURNAL ARTICLE
Zhongwen Lu, Yongsheng Pan, Songbo Wang, Jiajin Wu, Chenkui Miao, Zengjun Wang
Glycolysis-related metabolic reprogramming is a central hallmark of human cancers, especially in renal cell carcinoma. However, the regulatory function of glycolytic signature in papillary RCC has not been well elucidated. In the present study, the glycolysis-immune predictive signature was constructed and validated using WGCNA, glycolysis-immune clustering analysis. PPI network of DEGs was constructed and visualized. Functional enrichments and patients' overall survival were analyzed. QRT-PCR experiments were performed to detect hub genes' expression and distribution, siRNA technology was used to silence targeted genes; cell proliferation and migration assays were applied to evaluate the biological function...
April 15, 2024: European Journal of Medical Research
#6
Sunny Malde, Pranjal Kashiv, Sushrut Gupta, Shubham Dubey, Manish Balwani, Amit Pasari, Kapil N Sejpal, Prasad Gurjar
This case report details a 62-year-old male with a history of right renal cell carcinoma (RCC) who developed sunitinib-induced nephrotic syndrome during treatment. The patient had a complex medical history, including a right nephrectomy in 2009, brain metastasis excisions in 2011 and 2012, and prolonged sunitinib therapy. Hypothyroidism, hypertension, and various surgeries further complicated his clinical picture. In April 2022, the patient presented with bilateral pedal edema, acute kidney injury superimposed on chronic kidney disease, and proteinuria...
March 2024: Curēus
#7
JOURNAL ARTICLE
Zhenwei Wang, Zongtai Zheng, Bangqi Wang, Changxin Zhan, Xuefeng Yuan, Xiaoqi Lin, Qifan Xin, Zhihui Zhong, Xiaofu Qiu
Clear cell renal cell carcinoma (ccRCC) presents challenges in early diagnosis and effective treatment. In this study, we aimed to establish a prognostic model based on G2M checkpoint-related genes and identify associated clusters in ccRCC through clinical bioinformatic analysis and experimental validation. Utilizing a single-cell RNA dataset (GSE159115) and bulk-sequencing data from The Cancer Genome Atlas (TCGA) database, we analyzed the G2M checkpoint pathway in ccRCC. Differential expression analysis identified 45 genes associated with the G2M checkpoint, leading to the construction of a predictive model with four key genes (E2F2, GTSE1, RAD54L, and UBE2C)...
April 15, 2024: Heliyon
#8
REVIEW
Robert Roskoski
Kidney cancers comprise about 3% of all new malignancies in the United States. Renal cell carcinomas (RCCs) are the most common type of renal malignancy making up about 85% of kidney cancer cases. Signs and symptoms of renal cell carcinomas can result from local tumor growth, paraneoplastic syndromes, or distant metastases. The classic triad of presentation with flank pain, hematuria, and a palpable abdominal mass occurs in fewer than 10% of patients. Most diagnoses result from incidental imaging findings (ultrasonography or abdominal CT imaging) performed for another reason...
April 11, 2024: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
#9
JOURNAL ARTICLE
Linda Skibsted Kornerup, Mikkel Andreassen, Ulrich Knigge, Anne Kirstine Arveschoug, Per Løgstup Poulsen, Andreas Kjær, Peter Sandor Oturai, Henning Grønbæk, Gitte Dam
INTRODUCTION: Pheochromocytomas and paragangliomas are rare neuroendocrine tumours that originate from chromaffin cells within the adrenal medulla or extra-adrenal sympathetic ganglia. Management of disseminated or metastatic pheochromocytomas and paragangliomas continues to pose challenges and relies on limited evidence. METHOD: In this study, we report retrospective data on median overall survival (OS) and median progression-free survival (PFS) for all Danish patients treated with peptide receptor radionuclide therapy (PRRT) with 177 Lu-Dotatate or 90 Y-Dotatate over the past 15 years...
March 29, 2024: Cancers
#10
JOURNAL ARTICLE
Miltiadis Krokidis, Danae Fakitsa, Katerina Malagari, Theodoros Karampelas, Demosthenes Fokas, Constantin Tamvakopoulos, Achilles Chatziioannou
PURPOSE: Antiangiogenic agents have been used for many years as a first-line systemic treatment for advanced HCC. Embolization with cytostatic drugs on the other hand is the first-line treatment for intermediate HCC. The two types of drugs have not been combined for intraarterial delivery yet. The loading and release dynamics and the in vitro effect of their combination are tested in this experimental study. MATERIALS AND METHODS: Drug-eluting beads were loaded with doxorubicin, sunitinib and sunitinib analogue piperazine (SAP) alone and with their combinations...
April 12, 2024: Cardiovascular and Interventional Radiology
#11
REVIEW
Denise S Hoogenkamp, Linda J de Wit-van der Veen, Daphne M V Huizing, Margot E T Tesselaar, Rachel S van Leeuwaarde, Marcel P M Stokkel, Marnix G E H Lam, Arthur J A T Braat
PURPOSE OF REVIEW: To provide insights into the role of peptide receptor radionuclide therapy (PRRT) in patients with advanced neuroendocrine tumors (NET) and an overview of possible strategies to combine PRRT with locoregional and systemic anticancer treatments. RECENT FINDINGS: Research on combining PRRT with other treatments encompasses a wide variety or treatments, both local (transarterial radioembolization) and systemic therapies, chemotherapy (i.e., capecitabine and temozolomide), targeted therapies (i...
April 10, 2024: Current Oncology Reports
#12
REVIEW
Andrey Soares, Fernando Sabino Marques Monteiro, Karine Martins da Trindade, Adriano Gonçalves E Silva, Ana Paula Garcia Cardoso, André Deeke Sasse, André P Fay, André Paternò Castello Dias Carneiro, Antonio Machado Alencar Junior, Augusto César de Andrade Mota, Bruno Santucci, Daniel da Motta Girardi, Daniel Herchenhorn, Daniel Vilarim Araújo, Denis Leonardo Jardim, Diogo Assed Bastos, Diogo Rodrigues Rosa, Fabio A Schutz, Fábio Roberto Kater, Felipe da Silva Marinho, Fernando Cotait Maluf, Fernando Nunes Galvão de Oliveira, Fernando Vidigal, Igor Alexandre Protzner Morbeck, Jose Augusto Rinck Júnior, Leonardo Atem G A Costa, Manuel Caitano Dias Ferreira Maia, Manuela Zereu, Marcelo Roberto Pereira Freitas, Mariane Sousa Fontes Dias, Milena Shizue Tariki, Pamela Muniz, Patrícia Medeiros Milhomem Beato, Paulo Sérgio Moraes Lages, Pedro Isaacsson Velho, Ricardo Saraiva de Carvalho, Rodrigo Coutinho Mariano, Sandro Roberto de Araújo Cavallero, Thiago Martins Oliveira, Vinicius Carrera Souza, Oren Smaletz, Stênio de Cássio Zequi
PURPOSE: Renal cell carcinoma is an aggressive disease with a high mortality rate. Management has drastically changed with the new era of immunotherapy, and novel strategies are being developed; however, identifying systemic treatments is still challenging. This paper presents an update of the expert panel consensus from the Latin American Cooperative Oncology Group and the Latin American Renal Cancer Group on advanced renal cell carcinoma management in Brazil. METHODS: A panel of 34 oncologists and experts in renal cell carcinoma discussed and voted on the best options for managing advanced disease in Brazil, including systemic treatment of early and metastatic renal cell carcinoma as well as nonclear cell tumours...
April 9, 2024: Journal of Cancer Research and Clinical Oncology
#13
Yunlong Zhang, Changchun Li, Xiaobin Deng, Fumihiko Urabe, Mauricio Burotto, Sebastiano Buti, Giulia Claire Giudice, Zhenzhen Zhao, Chao Yang, Jian Sun, Yifei Du, Shan Wang
BACKGROUND: Microphthalmia-associated transcription factor/transcription factor E (MiTF/TFE) translocation renal cell carcinoma (RCC) is a rare type of non-clear cell RCC (nccRCC), which is more common in females. Currently, there is no standardized treatment for advanced metastatic microphthalmia translocation RCC (MiT-RCC). The main treatment modalities include surgery, chemotherapy, immunotherapy, anti-vascular endothelial growth factor or vascular endothelial growth factor receptor (VEGFR) inhibitors, mammalian target of rapamycin (mTOR) inhibitors, and targeted therapy against the mesenchymal-epithelial transition (MET) factor signaling pathway...
March 27, 2024: Translational Pediatrics
#14
JOURNAL ARTICLE
Robert J Motzer, Toni K Choueiri, Thomas Hutson, Sun Young Rha, Javier Puente, Aly-Khan A Lalani, Eric Winquist, Masatoshi Eto, Naveen S Basappa, Nizar M Tannir, Ulka Vaishampayan, Georg A Bjarnason, Stéphane Oudard, Viktor Grünwald, Joseph Burgents, Ran Xie, Jodi McKenzie, Thomas Powles
In the phase 3 CLEAR trial, lenvatinib plus pembrolizumab (L + P) showed superior efficacy versus sunitinib in treatment-naïve patients with advanced renal cell carcinoma (aRCC). The combination treatment was associated with a robust objective response rate of 71%. Here we report tumor responses for patients in the L + P arm in CLEAR, with median follow-up of ∼4 yr at the final prespecified overall survival (OS) analysis. Tumor responses were assessed by independent review using Response Evaluation Criteria in Solid Tumors v1...
April 5, 2024: European Urology
#15
JOURNAL ARTICLE
Rania A Elrashidy, Hoda E Mohamed, Sara M Abdel Aal, Samar R Mohamed, Sara M Tolba, Yasmin K Mahmoud
Sunitinib (SUN) is a chemotherapeutic agent clinically approved for treatment of metastatic renal carcinoma. Despite its remarkable benefits, various renal toxicities have been reported that limit its clinical uses. Oleuropein (OLE) is the main polyphenolic constituent of olive tree and mediates the majority of its valuable pharmacological activities. The current study examined the probable renoprotective effects of OLE against SUN-induced nephrotoxicity. Adult male albino rats were co-treated by SUN (25mg/kg, 3 times/week, PO) with either a drug vehicle or OLE (60mg/kg/day, daily, PO) for four weeks...
April 4, 2024: Archives of Biochemistry and Biophysics
#16
JOURNAL ARTICLE
Takashi Sawada, Mamoru Narukawa
BACKGROUND: Combination therapy with multiple tyrosine kinase inhibitors (multi-TKIs) and immune checkpoint inhibitors (ICIs) has been increasingly tested in clinical studies. This study aimed to investigate the effect of the addition of ICI to multi-TKIs on the profile of treatment-related adverse events. METHODS: An electronic database search was performed using PubMed and Web of Science to identify published clinical studies on multi-TKI monotherapy and multi-TKI plus ICI combination therapy from July 20, 2005 to July 1, 2023...
2024: Cancer Control: Journal of the Moffitt Cancer Center
#17
JOURNAL ARTICLE
Srinivas Ananth Kumar, Bhagwant Rai Mittal, Suraj Kumar, Harmandeep Singh, Rajender Kumar, Amanjit Bal
Renal cell carcinoma (RCC) is a leading cause of mortality among genitourinary malignancies with limited therapeutic options. The hematogenous route, lymphatic spread, and direct invasion have been documented in RCC. Usually, metastases are regional lymph nodes, lungs, bone, liver, adrenal glands, contralateral kidney, and brain. Metastases to the rare sites such as skin, breast, head and neck were documented in the literature. In the present case, we describe the synchronous metastases to the base of the tongue and thyroid gland in RCC and the response to sunitinib therapy on 18F-FDG PET/CT...
May 1, 2024: Clinical Nuclear Medicine
#18
JOURNAL ARTICLE
Edward Lloyd Briercheck, J Michael Wrigglesworth, Ines Garcia-Gonzalez, Catherina Scheepers, Mei Ching Ong, Viji Venkatesh, Philip Stevenson, Alicia A Annamalay, David G Coffey, Aparna B Anderson, Pat Garcia-Gonzalez, Michael J Wagner
IMPORTANCE: Gastrointestinal stromal tumor (GIST) is a rare cancer treated with the tyrosine kinase inhibitors imatinib mesylate or sunitinib malate. In general, in low- and middle-income countries (LMICs), access to these treatments is limited. OBJECTIVE: To describe the demographic characteristics, treatment duration, and survival of patients with GIST in LMICs treated with imatinib and sunitinib through The Max Foundation programs. DESIGN, SETTING, AND PARTICIPANTS: This retrospective database cohort analysis included patients in 2 access programs administered by The Max Foundation: the Glivec International Patient Assistance Program (GIPAP), from January 1, 2001, to December 31, 2016, and the Max Access Solutions (MAS) program, January 1, 2017, to October 12, 2020...
April 1, 2024: JAMA Network Open
#19
Zhixiang Gao, Lu Jin, Haijun Lv, Nengliang Duan, Guoneng Zhang, Yuanshuai Ran, Boxin Xue, Xiaolong Liu
In recent years, with the in-depth study of PD-1/PD-L1 related pathways, great progress has been made in cancer immunotherapy. However, the immunotherapy regimen for mccRCC is still controversial in clinical practice. A 50-year-old man with mccRCC complicated with renal venous tumor thrombus from 2019 to present, including surgical treatment, targeted therapy and the combined treatment regimen of "Tislelizumab combined with Sunitinib". Although he experienced a roller coaster of adverse reactions during treatment, the patient's prognosis was good...
May 2024: Urology Case Reports
#20
JOURNAL ARTICLE
Hoda E Mohamad, Mervat E Askar, Mohamed A Shaheen, Nourhan M Baraka, Yasmin K Mahmoud
We aimed in this study to investigate the possible cardioprotective effects of sacubitril/valsartan against sunitinib-induced cardiac fibrosis (CF) and oxidative stress via targeting thioredoxin-interacting protein/thioredoxin (TXNIP/TRX) system and nuclear factor-kappa B (NF-κB)/Wingless-related MMTV integration site (Wnt)/β-catenin/Sex-determining region Y box 9 (SOX9) signaling. CF was induced in male Wistar albino rats by cumulative dose of sunitinib (300 mg/kg, given over 4 weeks as: 25 mg/kg orally, three times a week), which were co-treated with sacubitril/valsartan (68 mg/kg/day, orally) for four weeks...
March 31, 2024: International Immunopharmacology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
